2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2519

Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Abstract Number: 2520

Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
Abstract Number: 2521

Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Abstract Number: 2522

Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
Abstract Number: 2523

Reasons for Provider Non-Adherence to a Treat to Target Strategy in Rheumatoid Arthritis
Abstract Number: 2524

Achievement of Imaging Remission Among Patients with Rheumatoid Arthritis in Clinical Remission and Their Characteristics
Abstract Number: 2525

Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Abstract Number: 2526

TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Abstract Number: 2527

Drug Retention of Biologics in Rheumatoid Arthritis Patients: The Role of Baseline Characteristics and Impact of Time-Varying Factors
Abstract Number: 2528

Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Abstract Number: 2529

Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Abstract Number: 2530

Patient´s Motivations for Non-Persistence with Medication Impact How They Score Compliance
Abstract Number: 2531

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Abstract Number: 2532

Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis
Abstract Number: 2533

Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].